[go: up one dir, main page]

PE20061113A1 - Compuestos heterociclos como agonistas de ligandos selectivos de erb - Google Patents

Compuestos heterociclos como agonistas de ligandos selectivos de erb

Info

Publication number
PE20061113A1
PE20061113A1 PE2006000026A PE2006000026A PE20061113A1 PE 20061113 A1 PE20061113 A1 PE 20061113A1 PE 2006000026 A PE2006000026 A PE 2006000026A PE 2006000026 A PE2006000026 A PE 2006000026A PE 20061113 A1 PE20061113 A1 PE 20061113A1
Authority
PE
Peru
Prior art keywords
erb
agonists
selective ligands
compounds
hydroxyphenil
Prior art date
Application number
PE2006000026A
Other languages
English (en)
Inventor
Mark Day
Heather A Harris
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of PE20061113A1 publication Critical patent/PE20061113A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A61K31/055—Phenols the aromatic ring being substituted by halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA I, II, DONDE R1 ES H, HIDROXILO, HALOGENO, ALQUILO C1-C6, ENTRE OTROS; R2 Y R2a SON CADA UNO H, HIDROXILO, HALOGENO, ALCOXI C1-C4, ALQUINILO C2-C7, ENTRE OTROS; R3, R3a Y R4 SON CADA UNO H, ALQUILO C1-C6, ALQUENILO C2-C7, HALOGENO, ALCOXI C1-C4, ENTRE OTROS; X ES O, S, NH, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 7-(3-HIDROXIFENIL)-2-NAFTOL; 6-(4-HIDROXIFENIL)-2-NAFTOL; 6-(4-HIDROXIFENIL)-1-FENIL-2-NAFTOL; ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA Y A UN METODO DE TRATSMIENTO. DICHOS COMPUESTOS SON LIGANDOS SELECTIVOS DEL RECEPTOR DE ESTROGENOS-BETHA (ERBETHA) UTILES EN EL TRATAMIENTO DE PARKINSON
PE2006000026A 2004-12-17 2006-01-03 Compuestos heterociclos como agonistas de ligandos selectivos de erb PE20061113A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US63714404P 2004-12-17 2004-12-17

Publications (1)

Publication Number Publication Date
PE20061113A1 true PE20061113A1 (es) 2006-11-06

Family

ID=36143266

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006000026A PE20061113A1 (es) 2004-12-17 2006-01-03 Compuestos heterociclos como agonistas de ligandos selectivos de erb

Country Status (20)

Country Link
US (1) US20060135574A1 (es)
EP (1) EP1824478A2 (es)
JP (1) JP2008524236A (es)
KR (1) KR20070086329A (es)
CN (1) CN101321524A (es)
AR (1) AR051844A1 (es)
AU (1) AU2005316561A1 (es)
BR (1) BRPI0519111A2 (es)
CA (1) CA2590258A1 (es)
GT (1) GT200500370A (es)
IL (1) IL183604A0 (es)
MX (1) MX2007007347A (es)
NI (1) NI200700152A (es)
NO (1) NO20072658L (es)
PA (1) PA8656601A1 (es)
PE (1) PE20061113A1 (es)
RU (1) RU2007120254A (es)
TW (1) TW200637545A (es)
WO (1) WO2006065968A2 (es)
ZA (1) ZA200705103B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070191442A1 (en) * 2006-02-14 2007-08-16 Wyeth Aqueous Pharmaceutical Formulations of ER-beta Selective Ligands
US10149982B2 (en) 2009-03-11 2018-12-11 University Of South Florida Prevention and treatment of brain diseases and disorders related to abnormal protein aggregation through electromagnetic field treatment
WO2010105035A2 (en) * 2009-03-11 2010-09-16 University Of South Florida Prevention, treatment, and diagnosis of alzheimer's disease through electromagnetic field exposure
CA2959753A1 (en) 2014-09-02 2016-03-10 The Regents Of The University Of California Estrogen receptor ligand treatment for neurodegenerative diseases
US20210340155A1 (en) * 2017-03-30 2021-11-04 Marquette University Substituted (4-Hydroxyphenyl)Cycloalkane and (4-Hydroxyphenyl)Cycloalkene Compounds and Uses Thereof as Selective Agonists of the Estrogen Receptor Beta Isoform for Enhanced Memory Consolidation

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5990078A (en) * 1995-07-14 1999-11-23 The Trustees Of Columbia University In The City Of New York Means of increasing estrogen receptor levels in neural tissue
FR2739777B1 (fr) * 1995-10-11 1997-11-14 Cird Galderma Ligand antagoniste rar-gamma ou agoniste rar-alpha en tant qu'inhibiteur d'apoptose
AU5260698A (en) * 1996-11-18 1998-06-10 Internutria, Inc. Composition and treatment for persistent reproductive transition symptoms
US20040092010A1 (en) * 2002-04-15 2004-05-13 Ariel Ruiz I Altaba Method of proliferating and inducing brain stem cells to differentiate to neurons
TR200102992T2 (tr) * 1999-04-16 2004-12-21 Astrazeneca Ab ß östrojen reseptörü ligandları.
WO2002046168A1 (en) * 2000-12-07 2002-06-13 Astrazeneca Ab Therapeutic benzimidazole compounds
US7045539B2 (en) * 2000-12-22 2006-05-16 Astrazeneca Ab Therapeutic benzoxazole compounds
US20030096264A1 (en) * 2001-06-18 2003-05-22 Psychiatric Genomics, Inc. Multi-parameter high throughput screening assays (MPHTS)
ATE313803T1 (de) * 2001-11-07 2006-01-15 Schering Ag In vitro screening nach liganden des östrogenrezeptors
UA83620C2 (ru) * 2001-12-05 2008-08-11 Уайт Замещенные бензоксазолы и их аналоги как эстрогенные агенты
TW200301107A (en) * 2001-12-13 2003-07-01 Wyeth Corp Substituted 6H-dibenzo[c,h]chromenes as estrogenic agents
US6914074B2 (en) * 2001-12-13 2005-07-05 Wyeth Substituted phenyl naphthalenes as estrogenic agents
US6774248B2 (en) * 2001-12-18 2004-08-10 Wyeth Substituted 2-phenyl benzofurans as estrogenic agents
EP1542665A1 (en) * 2002-09-19 2005-06-22 Merck & Co., Inc. Method for treating depression and/or anxiety
CL2004000985A1 (es) * 2003-05-16 2005-01-14 Wyeth Corp Compuestos derivados de fenilquinolinas; composicion farmaceutica, proceso de preparacion; y uso para tratar osteoporosis, enfermedad de paget, dano vascular, osteoartritis, cancer oseo, cancer ovarico, cancer prostatico, hipercolesterolemia, aterosc
US7157492B2 (en) * 2004-02-26 2007-01-02 Wyeth Dibenzo chromene derivatives and their use as ERβ selective ligands
CN1993343A (zh) * 2004-07-01 2007-07-04 惠氏公司 作为雌激素配体的四环化合物

Also Published As

Publication number Publication date
WO2006065968A8 (en) 2008-09-12
MX2007007347A (es) 2007-07-13
KR20070086329A (ko) 2007-08-27
RU2007120254A (ru) 2009-01-27
AU2005316561A1 (en) 2006-06-22
NI200700152A (es) 2008-06-17
ZA200705103B (en) 2009-11-25
WO2006065968A2 (en) 2006-06-22
AR051844A1 (es) 2007-02-14
US20060135574A1 (en) 2006-06-22
JP2008524236A (ja) 2008-07-10
NO20072658L (no) 2007-09-12
PA8656601A1 (es) 2006-12-07
CN101321524A (zh) 2008-12-10
WO2006065968A3 (en) 2008-04-10
TW200637545A (en) 2006-11-01
GT200500370A (es) 2006-07-13
CA2590258A1 (en) 2006-06-22
BRPI0519111A2 (pt) 2008-12-23
IL183604A0 (en) 2007-10-31
EP1824478A2 (en) 2007-08-29

Similar Documents

Publication Publication Date Title
PE20080842A1 (es) Benzoxazoles y oxazolopiridinas que son utiles como inhibidores de las cinasas janus
PE20080403A1 (es) Derivados heterociclicos fusionados y metodos de uso
PE20090900A1 (es) Derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol como inhibidores del receptor del factor de creciemiento de hepatocitos (met), su procedimiento de preparacion y una composicion farmaceutica que los contiene
PE20071322A1 (es) Derivados de 2-morfolinopirimidina como inhibidores de fosfatidinoinositol(pi) 3-quinasa
PE20090960A1 (es) Derivados de quinazolinadiona, su preparacion y sus aplicaciones terapeuticas
PE20090279A1 (es) Derivados de 3,3-espiroindolinona como agentes antagonistas de mdm2
PE20080893A1 (es) Triazoles biciclicos como moduladores de la proteina cinasa
PE20081845A1 (es) Nuevos derivados de aminopirimidina como inhibidores de plk1
PE20090511A1 (es) Imidazopiridinonas
PE20121158A1 (es) Derivados de feniletinilo como moduladores alostericos positivos (map)
PE20060297A1 (es) Nuevos derivados fluoroglicosidicos de pirazoles como inhibidores de sglt 1
PE20040934A1 (es) Derivados de pirimidina como inhibidores selectivos de tirosina quinasas
PE20040165A1 (es) Uso de analogos del benzimidazol en el tratamiento de la proliferacion celular
PE20050482A1 (es) Derivados de dihidrobenzofuranilo alcanamida
PE20070983A1 (es) COMPUESTOS DERIVADOS DE 3-DESAZAPURINA COMO AGONISTAS DEL RECEPTOR Toll-LIKE (TLR7)
PE20040168A1 (es) Compuestos de pirrolopiridazina como inhibidores de las proteina cinasas
PE20061442A1 (es) Heterociclicos como agonistas del receptor de acido nicotinico para el tratamiento de dislipidemia
PE20100055A1 (es) Derivados de indolpiridina como moduladores de la sintasa de aldosterona
PE20060525A1 (es) Compuestos heterociclicos como inhibidores de cetp
PE20080948A1 (es) Derivados de imidazol como moduladores de la senda de hedgehog
PE20060185A1 (es) ANTAGONISTA DEL RECEPTOR A2A DE LA ADENOSINA CON ESTRUCTURA DE PIRAZOLO--[4,3-e]-1,2,4-TRIAZOLO-[1,5-c]-PIRIMIDINA
PE20090718A1 (es) Derivados de espiroindolinona
PE20091818A1 (es) DERIVADOS POLISUSTITUIDOS DE 2-ARIL-6-FENIL-IMIDAZO[1,2-a] PIRIDINAS, SU PREPARACION Y SU APLICACION EN TERAPEUTICA
PE20080182A1 (es) Derivados pirrolo-quinoxalinona como antibacterianos
PE20091056A1 (es) PIRIDO[3,2-e]PIRAZINAS, SU PROCEDIMIENTO DE PREPARACION Y USO COMO INHIBIDORES DE FOSFODIESTERASA 10

Legal Events

Date Code Title Description
FX Voluntary withdrawal